EW vs. SNN: Edwards Lifesciences vs. Smith & Nephew Stock Comparison

Company Profile

Edwards Lifesciences (EW) and Smith & Nephew (SNN) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Edwards Lifesciences (EW) trades as ordinary local shares, while Smith & Nephew (SNN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Edwards Lifesciences (EW) at 9.33% and Smith & Nephew (SNN) at 11.85% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

For every dollar of sales, both Edwards Lifesciences (EW) at 15.30% and Smith & Nephew (SNN) at 10.08% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Edwards Lifesciences (EW) at 30.15% and Smith & Nephew (SNN) at 14.47% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Edwards Lifesciences (EW) at 11.55% and Smith & Nephew (SNN) at 6.09% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Smith & Nephew (SNN) at 52.34% sits in the top EPS growth quartile, while Edwards Lifesciences (EW) at -73.74% is in the bottom quartile, showing a clear gap in earnings momentum.

Growth Metrics

Financial Strength

Smith & Nephew (SNN) at 2.14 keeps current ratio within its industry’s typical mid-range, while Edwards Lifesciences (EW) at 4.60 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Edwards Lifesciences (EW) at 0.06 keeps leverage in the lower industry quartile, while Smith & Nephew (SNN) at 0.73 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Edwards Lifesciences (EW) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a yield of 1.24%, ranking against industry peers normally.

Edwards Lifesciences (EW) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a payout of 53.20%, ranking against industry peers normally.

Dividend Metrics

Valuation

Smith & Nephew (SNN) at 21.19 is near its industry’s usual P/E ratio, while Edwards Lifesciences (EW) at 59.38 sits in the richer quartile — EW needs stronger growth or earnings quality to justify the premium.

Smith & Nephew (SNN) at 2.07 is priced about in line with its industry on P/S ratio, while Edwards Lifesciences (EW) at 8.80 sits in the pricier quartile — EW costs more per dollar of sales.

Edwards Lifesciences (EW) at 5.41 sits near its industry’s typical P/B ratio, while Smith & Nephew (SNN) at 12.80 prices above its benchmark range — SNN looks rich relative to book.

Valuation Metrics